EU urges clampdown on cosmetic misuse of Novo's Ozempic amid worsening drug shortages for diabetics [Fortune]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Fortune
Member states should consider “measures to control and optimize distribution of these medicines,” the umbrella group that monitors EU drug-supply issues said Wednesday. Drugmakers will also need to ensure that their marketing messages are cleared by regulatory authorities, the group said. The success of Novo Nordisk A/S's Ozempic and Wegovy as well as blockbuster shots made by rival Eli Lilly & Co., which can help people lose unprecedented amounts of weight, has left some patients with diabetes struggling to continue their treatment. The shortages will probably not be resolved this year, Emer Cooke, executive director of the European Medicines Agency, said at a press conference. “We cannot ignore that there is a rise in off-label use by people who are not living with diabetes,” she said. The obesity versions of the medicines have been slower to roll out in Europe, stoking demand for the sister products intended for diabetes. Up-front negotiating on price is often part of talks
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Fixing the Broken Rung: Better approaches to promotion and talent development [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN [Yahoo! Finance]Yahoo! Finance
- Keep faith in China, Li Qiang tells business at ‘Summer Davos' [Yahoo! Finance]Yahoo! Finance
- SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women [Yahoo! Finance]Yahoo! Finance
- Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 6/26/24 - Form 6-K
- 6/24/24 - Form 6-K
- 6/21/24 - Form 11-K
- NVO's page on the SEC website